Aduro Biotech, a biopharmaceutical company with three distinct immunotherapy technologies, said it is partnering with Merck to try a new combination of therapies to fight gastric cancer.
The companies will investigate the combination of Aduro’s experimental drug CRS-207 with Merck’s anti-PD-1 therapy Keytruda, or pembrolizumab, for the treatment of gastric cancer.
The phase 1 study, planned to begin in H1, will enroll patients with metastatic gastric cancer who have failed at least two prior therapies, Aduro said. Aduro rose 0.8% on Monday. Merck also rose 0.8% to a three week high.